Breaking News

HilleVax Lays Off 40% of Workforce

Aims to preserve cash while maintaining core capabilities.

HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, has announced a workforce reduction of 40%—or about 41 employees—to reduce its operating expenses.
 
The layoffs are intended to preserve cash while maintaining core capabilities as the company explores the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates as well as business development-related activities for these vaccine candidates.
 
Read about more layoffs in the biopharma sector.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters